HEALTHSTREAM INC
HealthStream provides software and services for healthcare organizations, professionals, and students to support workforce learning and development, governance, risk and compliance, staff scheduling, and medical staff credentialing, privileging, and enrollment. Its SaaS applications include learning, credentialing, and scheduling suites, along with tools for competency management, assessment, simulation-based education, clinical onboarding, and other workforce needs. The hStream technology platform supports interoperability across applications, while direct-to-student and professional career networks serve individual healthcare workers and students. HealthStream makes money primarily through subscription fees for its platform and products, priced according to subscriptions, solutions, and other factors. It also charges for implementation and training services and sells some products directly to individuals at per-unit retail prices. Its customers include healthcare providers, pharmaceutical and medical device companies, nursing schools, and students. HealthStream is headquartered in Nashville, Tennessee.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
HEALTHSTREAM INC (HSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. HealthStream Announces Third Quarter 2026 Results Page 1 November 2, 2026 Exhibit 99.1 Contact: Scott A. Roberts Chief Financial Officer (615) 301-3182 ir@healthstream.com Media: Mollie Condra, Ph.D. Head, Investor Relations & Communications (615) 301-3237 mollie.condra@healthstr
HealthStream reported Q3 2026 revenue growth of 8.9% to $83.3M, but operating income fell 13% to $6.6M. Net income declined 11.7% to $5.4M, while adjusted EBITDA rose 1% to $19.3M. The company received $40M from a private stock placement and declared a $0.035 quarterly dividend. Full-year 2026 guidance was updated, with revenue expected between $331M and $333M.
HealthStream (HSTM) will release Q3'26 earnings on November 02. Analysts expect revenue of $82.24M and EPS of $0.16. Results will be announced after market close at 4:00 PM ET.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning HSTM (HEALTHSTREAM INC). Coverage has skewed bullish: 2 bullish, 2 neutral, and 1 bearish.
Recent HSTM coverage spans earnings, market movers and financial news.
In the last 30 days, HSTM insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($420K). The most active reporter was REBROVICK LINDA with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Q3 showed revenue growth but operating income and net income declines, while 2026 guidance was updated, creating a mixed earnings and margin narrative.
Earnings miss on operating income and modest guidance may pressure the stock.
Pre‑release estimate may set market expectations; actual results could cause price move.
The modest beat in consensus forecasts may support a short‑term price uptick ahead of the earnings call.
Earnings miss on profit but revenue beat expectations; market may price in modest downside.
AlphAI scores every news story that mentions HSTM with an AI model for sentiment and relevance, and aggregates insider trades from HEALTHSTREAM INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
HEALTHSTREAM INC (HSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. HealthStream Announces Third Quarter 2026 Results Page 1 November 2, 2026 Exhibit 99.1 Contact: Scott A. Roberts Chief Financial Officer (615) 301-3182 ir@healthstream.com Media: Mollie Condra, Ph.D. Head, Investor Relations & Communications (615) 301-3237 mollie.condra@healthstr
6 min readHealthStream reported Q3 2026 revenue growth of 8.9% to $83.3M, but operating income fell 13% to $6.6M. Net income declined 11.7% to $5.4M, while adjusted EBITDA rose 1% to $19.3M. The company received $40M from a private stock placement and declared a $0.035 quarterly dividend. Full-year 2026 guidance was updated, with revenue expected between $331M and $333M.
3 min readHealthStream (HSTM) will release Q3'26 earnings on November 02. Analysts expect revenue of $82.24M and EPS of $0.16. Results will be announced after market close at 4:00 PM ET.
1 min readCitizens reiterated a Market Perform rating on HealthStream (HSTM) ahead of its Q3 earnings report. The stock is near its 52-week high at $34.86, up 63% in six months. Citizens expects Q3 revenue of $82.5M and EBITDA of $18.5M, slightly above consensus. HSTM reported Q2 earnings beating expectations, with revenue up 12.5% YoY. Freedom Capital initiated coverage with a Hold rating and $36 target.
2 min readHealthStream Inc. reports Q3 earnings with analysts expecting $0.16 EPS on $82.24M revenue, down 21% YoY in profit but up 7.5% in revenue. The company is shifting from low-growth learning management to an integrated clinical workforce platform. Shares trade near 52-week highs at $34.59 with a market cap of $1.03B. Analysts have a mean price target of $35, implying 1.2% upside. Key focus areas include sustaining growth momentum and learner engagement challenges.
2 min readFreedom Capital Markets initiated coverage of HealthStream with a Hold rating and $36 price target, implying 6.7% upside. The company is a leader in healthcare software, with 97% recurring revenue and $685M in RPO, indicating stability.
1 min readBiotech stocks BIIB, RTSN, CON, HNGE, and HSTM reached 52-week highs on October 12, 2026. BIIB hit $230.49 after positive clinical data for Litifilimab. RTSN rose 7% to $11.32 post-IPO. CON reported Q2 revenue growth of 10% to $606M. HNGE saw Q2 revenue rise 53% to $212M and acquired Cylinder Health. HSTM's Q2 revenue grew 12.5% to $83.7M.
2 min readPacira BioSciences (PCRX) surged 44% to $36.46 after Vitaris agreed to acquire it for $1.65B. Veradermics (MANE) rose 14% to $136.72, while HealthStream (HSTM) gained 2% to $32.42. Concentra (CON) and Haemonetics (HAE) also hit 52-week highs on strong financials.
2 min readAbbVie (ABBV) hit a 52-week high of $274.94 after receiving FDA Breakthrough Therapy designations for Temab-A. HealthStream (HSTM) rose 2% to $32.42, reporting Q2 revenue growth of 12.5%. Organon (OGN) reached $13.79, with FDA review of MIUDELLA expected by Q2 2027. All three companies hit 52-week highs on October 6, 2026.
2 min readHEALTHSTREAM INC (HSTM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On September 18, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of HealthStream, Inc. (the “Co
1 min read
